A Technique for Measuring Transcription Factor Activity
测量转录因子活性的技术
基本信息
- 批准号:10204040
- 负责人:
- 金额:$ 28.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-05 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AlgorithmsAntibodiesBehaviorBindingBinding SitesBiological AssayCellsChromatinDNAData SetDiseaseDrug ScreeningESR1 geneEngineeringEnhancersEstradiolFamilial Platelet DisorderGenesGenetic TranscriptionGoalsGrantHumanHuman GenomeLocationMalignant NeoplasmsMeasuresMethodsModelingMutationNucleic Acid Regulatory SequencesPatternPolymerasePost-Translational Protein ProcessingProtein IsoformsProteinsPublishingRNARegulationReporterResearchSiteStimulusStressTechniquesTechnologyTimeUnited States National Institutes of HealthVariantWaardenburg syndromeWorkcell typechromatin immunoprecipitationcookingdisease-causing mutationexperienceexperimental studygenome-widehuman diseaseimprovedmachine learning algorithmnovelnovel strategiesprototyperesponsetranscription factor
项目摘要
Summary
Almost every division of NIH has invested heavily in understanding transcription factors (TFs). TFs are
the managers of the cell, controlling everything from cell type to cellular response to stress. With their great
power, it is no wonder, many human disorders (cancer, familial platelet disorder, Waardenburg syndrome,
etc.) result from mutations in transcription factors. Moreover, over 75% of disease causing variants within the
human genome reside in regulatory regions, which are dense with TF binding sites. Currently we can
measure the location of TF binding, but binding does not equate with regulatory activity. Furthermore,
binding analysis is conducted one TF at a time. What is desperately needed is a technology that is able to
measure the activity of all TFs in a cell simultaneously. We have developed a novel approach, called eRNA
profiling, that leverages enhancer RNAs to infer the activity of all TFs in a cell simultaneously. In this grant we
seek to optimize our technology, making eRNA profiling more accurate, fast and broadly applicable.
总结
几乎NIH的每个部门都投入了大量资金来了解转录因子(TF)。TF是
细胞的管理者,控制着从细胞类型到细胞对压力的反应的一切。他们伟大的
权力,这是不足为奇的,许多人类疾病(癌症,家族性血小板疾病,Waardenburg综合征,
等等)。是由转录因子的突变引起的。此外,超过75%的致病变异在
人类基因组存在于调节区,其密集有TF结合位点。目前我们可以
测量TF结合的位置,但结合并不等同于调节活性。此外,委员会认为,
每次进行一个TF的结合分析。我们迫切需要的是一种技术,
同时测量细胞中所有TF的活性。我们开发了一种新的方法,称为eRNA
profiling,利用增强子RNA同时推断细胞中所有TF的活性。在这份协议中,我们
寻求优化我们的技术,使eRNA分析更准确,更快速,更广泛地适用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robin DeAnne Dowell-Deen其他文献
Robin DeAnne Dowell-Deen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robin DeAnne Dowell-Deen', 18)}}的其他基金
A Technique for Measuring Transcription Factor Activity
测量转录因子活性的技术
- 批准号:
10351235 - 财政年份:2018
- 资助金额:
$ 28.76万 - 项目类别:
A Technique for Measuring Transcription Factor Activity
测量转录因子活性的技术
- 批准号:
10430968 - 财政年份:2018
- 资助金额:
$ 28.76万 - 项目类别:
A Technique for Measuring Transcription Factor Activity
测量转录因子活性的技术
- 批准号:
10389701 - 财政年份:2018
- 资助金额:
$ 28.76万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 28.76万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 28.76万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 28.76万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 28.76万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 28.76万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 28.76万 - 项目类别: